These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 17200334)
1. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Arnold NB; Arkus N; Gunn J; Korc M Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633 [TBL] [Abstract][Full Text] [Related]
3. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. Susanto JM; Colvin EK; Pinese M; Chang DK; Pajic M; Mawson A; Caldon CE; Musgrove EA; Henshall SM; Sutherland RL; Biankin AV; Scarlett CJ Int J Oncol; 2015 May; 46(5):2223-30. PubMed ID: 25695794 [TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Zhou W; Feng X; Han Han ; Guo S; Wang G Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433 [TBL] [Abstract][Full Text] [Related]
5. Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils. Senthilkumar P; Gogoi B; Dhan SS; Subramani R; Pushparaj C; Mahesh A Drug Dev Res; 2024 Apr; 85(2):e22172. PubMed ID: 38488434 [TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer. Knoche SM; Brumfield GL; Goetz BT; Sliker BH; Larson AC; Olson MT; Poelaert BJ; Bavari A; Yan Y; Black JD; Solheim JC PLoS One; 2022; 17(9):e0273518. PubMed ID: 36126055 [TBL] [Abstract][Full Text] [Related]
7. Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs. Yang X; Xu Y; Brooks A; Guo B; Miskimins KW; Qian SY Free Radic Biol Med; 2016 Aug; 97():342-350. PubMed ID: 27368132 [TBL] [Abstract][Full Text] [Related]
8. Exploring the anti-EBV potential of suberoylanilide hydroxamic acid: Induction of apoptosis in infected cells through suppressing BART gene expression and inducing lytic infection. Liu Y; Wai AP; Zolzaya T; Iida Y; Okada S; Iizasa H; Yoshiyama H Virology; 2024 Sep; 597():110161. PubMed ID: 38981317 [TBL] [Abstract][Full Text] [Related]
9. Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells. Chou PJ; Sarwar MS; Wang L; Wu R; Li S; Hudlikar RR; Wang Y; Su X; Kong AN Cancer Prev Res (Phila); 2023 Jun; 16(6):321-332. PubMed ID: 36867722 [TBL] [Abstract][Full Text] [Related]
10. Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit. Wang Y; Zhang J; Li K; Xia S; Gou S J Med Chem; 2024 Feb; 67(3):2066-2082. PubMed ID: 38261411 [TBL] [Abstract][Full Text] [Related]
11. SAHA/5-AZA Enhances Acetylation and Degradation of mutp53, Upregulates p21 and Downregulates c-Myc and BRCA-1 in Pancreatic Cancer Cells. Di Crosta M; Ragone FC; Benedetti R; D'Orazi G; Gilardini Montani MS; Cirone M Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000128 [TBL] [Abstract][Full Text] [Related]
13. The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation. Samuni Y; Flores-Santana W; Krishna MC; Mitchell JB; Wink DA Free Radic Biol Med; 2009 Aug; 47(4):419-23. PubMed ID: 19447172 [TBL] [Abstract][Full Text] [Related]
14. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Terry SY; Vallis KA Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1298-305. PubMed ID: 22336201 [TBL] [Abstract][Full Text] [Related]
16. Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock. Finkelstein RA; Li Y; Liu B; Shuja F; Fukudome E; Velmahos GC; deMoya M; Alam HB J Surg Res; 2010 Sep; 163(1):146-54. PubMed ID: 20599223 [TBL] [Abstract][Full Text] [Related]
17. Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cells. Li X; Kong R; Hou W; Cao J; Zhang L; Qian X; Zhao L; Ying W Cell Oncol (Dordr); 2024 Feb; 47(1):141-156. PubMed ID: 37639207 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells. Kakwere H; Ingham ES; Tumbale SK; Ferrara KW Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111251. PubMed ID: 32919625 [TBL] [Abstract][Full Text] [Related]
19. Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. Zhou X; Guo Z; Liu S; Chen Z; Wang Y; Yang R; Li X; Ma K Phytomedicine; 2024 Jan; 122():155128. PubMed ID: 37839227 [TBL] [Abstract][Full Text] [Related]
20. The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. Mahalingam D; Patel S; Nuovo G; Gill G; Selvaggi G; Coffey M; Nawrocki ST BMC Cancer; 2015 Jul; 15():513. PubMed ID: 26156229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]